Pub Date : 2019-03-01DOI: 10.35248/2329-6917.19.7.254
R. C. Founou, J. Nwobegahay, R. Gandji, Cedrice Tsayem, Sandra Yopa, M. Kuété, Luria Leslie Founou
Chronic lymphocytic leukemia (CLL) is an acquired monoclonal disorder characterized by a gradual accumulation of functionally incompetent lymphocytes. It generally presents a clonal B cells arrested in the B-cell differentiation pathway that resemble morphologically to mature lymphocytes in the peripheral blood. There is a scarcity of CLL data among sub-Saharan African countries such as Cameroon. We herein report a case of CLL that remained stable over a period of seven years in a 54 years old Black African man. The patient had no history of exposure to toxic chemicals or ionizing radiation and presented with several complaints and clinical symptoms. Clinical and laboratory investigations indicated a CLL in stage B of the Binet staging system. The dosage of chloraminophene led to a favourable outcome in the patient with the reduction of lymphocyte count, size of lymph nodes while relieving pain and improving general status and bone-marrow function of the patient.
{"title":"Chronic Lymphocytic Leukemia in a Black African Man: A Cameroonian Case Report","authors":"R. C. Founou, J. Nwobegahay, R. Gandji, Cedrice Tsayem, Sandra Yopa, M. Kuété, Luria Leslie Founou","doi":"10.35248/2329-6917.19.7.254","DOIUrl":"https://doi.org/10.35248/2329-6917.19.7.254","url":null,"abstract":"Chronic lymphocytic leukemia (CLL) is an acquired monoclonal disorder characterized by a gradual accumulation of functionally incompetent lymphocytes. It generally presents a clonal B cells arrested in the B-cell differentiation pathway that resemble morphologically to mature lymphocytes in the peripheral blood. There is a scarcity of CLL data among sub-Saharan African countries such as Cameroon. We herein report a case of CLL that remained stable over a period of seven years in a 54 years old Black African man. The patient had no history of exposure to toxic chemicals or ionizing radiation and presented with several complaints and clinical symptoms. Clinical and laboratory investigations indicated a CLL in stage B of the Binet staging system. The dosage of chloraminophene led to a favourable outcome in the patient with the reduction of lymphocyte count, size of lymph nodes while relieving pain and improving general status and bone-marrow function of the patient.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47734789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-30DOI: 10.35248/2329-6917.19.7.253
Kelly Cristina Santos Montanari, M. M. Fusuma, Alessandra Maria Dias Lacerda, L. Okuda, E. M. Pituco, A. F. Carvalho, V. Castro, R. Piatti, Eliana Scarcelli Pinheiro, R. Harakava, C. D. Fava
We investigated the infection of Bovine Leukemia Virus (BLV) related to other pathogens [Neospora caninum, Bovine Herpesvirus-1 (BoHV-1), Bovine Viral Diarrhea Virus (BVDV), and pathogenic bacteria] in 80 bovine aborted fetuses. The materials comprised whole fetuses, fetal organs, and placenta. The BLV was diagnosed by nested-PCR (env gp51 BLV gene), the identification of viral genotypes by sequencing, and the phylogenetic analysis by neighborjoining and maximum composite likelihood methods. The other pathogens and diagnoses were, respectively: Neospora caninum (nested-PCR), BoHV-1 (nested-PCR), BVDV (PCR), Brucella spp. (isolation and identification), Leptospira spp. (PCR), aerobic bacteria [Enterobacteriaceae, Gram positive cocci, Trueperella (Arcanobacterium) pyogenes] and micro-aerophilic (Campylobacter spp., Histophilus somni, and Listeria monocytogenes) by isolation and identification. BLV fetal antibodies were identified by ELISA kit. Thirteen (16.25%) fetuses were positive by BLV nested-PCR. Phylogenetic analysis revealed BLV genotypes 1, 5, and 6, which are frequently found in cattle in Brazil, Argentina, and Uruguay. No fetuses were positive for BLV antibodies by ELISA. A single case of coinfection with BLV was found for each of the pathogens Trueperella (Arcanobacterium) pyogenes, Klebsiella spp., and Streptococcus spp. were isolated as a pure or representing the preponderance of bacteria in a pooled culture. In the 67 BLV-negative fetuses, pathogens identified were single cases of Trueperella (Arcanobacterium) pyogenes, Staphylococcus aureus, and Brucella abortus; 2 of Escherichia coli; 3 of bovine viral diarrhea virus; and 4 of Neospora caninum. No pathogens were found in 55 fetuses. The low number of BLV positive samples infected or no by other pathogens didn´t allow performing statistical analysis for understanding if there were significative differences among not infected and infected BLV fetuses. Because BLV is an immunosuppressive agent and predisposes the cow to other pathogens, its connection with Leukemia or abortions need additional studies with bigger sampling, for elucidating pathogenesis in the pregnant cow and in the fetus. The rates of BLV transplacental transmission show the necessity of prophylactic measures in Brazilian cattle herds, in order to avoid infection in utero.
{"title":"Bovine Leukemia Virus in Bovine Aborted Fetuses","authors":"Kelly Cristina Santos Montanari, M. M. Fusuma, Alessandra Maria Dias Lacerda, L. Okuda, E. M. Pituco, A. F. Carvalho, V. Castro, R. Piatti, Eliana Scarcelli Pinheiro, R. Harakava, C. D. Fava","doi":"10.35248/2329-6917.19.7.253","DOIUrl":"https://doi.org/10.35248/2329-6917.19.7.253","url":null,"abstract":"We investigated the infection of Bovine Leukemia Virus (BLV) related to other pathogens [Neospora caninum, Bovine Herpesvirus-1 (BoHV-1), Bovine Viral Diarrhea Virus (BVDV), and pathogenic bacteria] in 80 bovine aborted fetuses. The materials comprised whole fetuses, fetal organs, and placenta. The BLV was diagnosed by nested-PCR (env gp51 BLV gene), the identification of viral genotypes by sequencing, and the phylogenetic analysis by neighborjoining and maximum composite likelihood methods. The other pathogens and diagnoses were, respectively: Neospora caninum (nested-PCR), BoHV-1 (nested-PCR), BVDV (PCR), Brucella spp. (isolation and identification), Leptospira spp. (PCR), aerobic bacteria [Enterobacteriaceae, Gram positive cocci, Trueperella (Arcanobacterium) pyogenes] and micro-aerophilic (Campylobacter spp., Histophilus somni, and Listeria monocytogenes) by isolation and identification. BLV fetal antibodies were identified by ELISA kit. Thirteen (16.25%) fetuses were positive by BLV nested-PCR. Phylogenetic analysis revealed BLV genotypes 1, 5, and 6, which are frequently found in cattle in Brazil, Argentina, and Uruguay. No fetuses were positive for BLV antibodies by ELISA. A single case of coinfection with BLV was found for each of the pathogens Trueperella (Arcanobacterium) pyogenes, Klebsiella spp., and Streptococcus spp. were isolated as a pure or representing the preponderance of bacteria in a pooled culture. In the 67 BLV-negative fetuses, pathogens identified were single cases of Trueperella (Arcanobacterium) pyogenes, Staphylococcus aureus, and Brucella abortus; 2 of Escherichia coli; 3 of bovine viral diarrhea virus; and 4 of Neospora caninum. No pathogens were found in 55 fetuses. The low number of BLV positive samples infected or no by other pathogens didn´t allow performing statistical analysis for understanding if there were significative differences among not infected and infected BLV fetuses. Because BLV is an immunosuppressive agent and predisposes the cow to other pathogens, its connection with Leukemia or abortions need additional studies with bigger sampling, for elucidating pathogenesis in the pregnant cow and in the fetus. The rates of BLV transplacental transmission show the necessity of prophylactic measures in Brazilian cattle herds, in order to avoid infection in utero.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41596197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/2329-6917.19.7.252
Karima A. Mahfouz, Abdelraoof A. Abo-Nar, Sara M. Bendary
{"title":"Role of Interleukin17F (IL17F) Gene Polymorphism in Susceptibility to Acute Myeloid Leukemia","authors":"Karima A. Mahfouz, Abdelraoof A. Abo-Nar, Sara M. Bendary","doi":"10.35248/2329-6917.19.7.252","DOIUrl":"https://doi.org/10.35248/2329-6917.19.7.252","url":null,"abstract":"","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69998527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/2329-6917.19.7.259
Shimuye Kalayu Yirga, Minhui Lin, Zhongyan Huang, Ji, A. Hu
Advancement of monoclonal antibodies (Mabs) to be accepted as a therapy has long history. This article describes the dramatic developmental trend of therapeutic antibody technology and their significant role for treatment of leukemia-lymphoma at the current time. The therapeutic Mab technology development from murine (mouse origin) to fully human resulted in low immunogenicity and high quality Mabs. Chemotherapy is standard care for leukemialymphoma treatments. However, it is associated with high toxicities (side effects), painful and relatively ineffective against certain leukemia-lymphoma subtypes. The remarkable contribution of Von Behring, Paul Ehrlich and the discovery of hybridoma technology marked the beginning of antibodies for therapeutic applications. Rituximab is the first Mab approved by Food and Drug Administration against B-cell malignancies. Today, a number of effective Mabs targeting leukemia and lymphoma were approved and successfully developed. The Mab therapeutic phenomena in the body (also called war in the blood) has various mechanism of cations. In recent years, Mab against leukemialymphoma achieved significantly therapeutic outcomes, eventually this led to traditional chemotherapy treatment free era. We also reviewed that, the therapeutic efficacy of Mabs against leukemia-lymphoma as compared antibody alone and antibody conjugated with potent chemotherapy or cytotoxic drugs. This article extends our understanding of advancements in therapeutic Mabs technology and provides new insights of Mab leukemia-lymphomas therapy. We also encourage further more studies for Mab based diagnostics, treatments of leukemia and lymphomas.
{"title":"Development of Therapeutic Antibody Technology And Recent Perspectives For Leukemia-Lymphoma Treatment","authors":"Shimuye Kalayu Yirga, Minhui Lin, Zhongyan Huang, Ji, A. Hu","doi":"10.35248/2329-6917.19.7.259","DOIUrl":"https://doi.org/10.35248/2329-6917.19.7.259","url":null,"abstract":"Advancement of monoclonal antibodies (Mabs) to be accepted as a therapy has long history. This article describes the dramatic developmental trend of therapeutic antibody technology and their significant role for treatment of leukemia-lymphoma at the current time. The therapeutic Mab technology development from murine (mouse origin) to fully human resulted in low immunogenicity and high quality Mabs. Chemotherapy is standard care for leukemialymphoma treatments. However, it is associated with high toxicities (side effects), painful and relatively ineffective against certain leukemia-lymphoma subtypes. The remarkable contribution of Von Behring, Paul Ehrlich and the discovery of hybridoma technology marked the beginning of antibodies for therapeutic applications. Rituximab is the first Mab approved by Food and Drug Administration against B-cell malignancies. Today, a number of effective Mabs targeting leukemia and lymphoma were approved and successfully developed. The Mab therapeutic phenomena in the body (also called war in the blood) has various mechanism of cations. In recent years, Mab against leukemialymphoma achieved significantly therapeutic outcomes, eventually this led to traditional chemotherapy treatment free era. We also reviewed that, the therapeutic efficacy of Mabs against leukemia-lymphoma as compared antibody alone and antibody conjugated with potent chemotherapy or cytotoxic drugs. This article extends our understanding of advancements in therapeutic Mabs technology and provides new insights of Mab leukemia-lymphomas therapy. We also encourage further more studies for Mab based diagnostics, treatments of leukemia and lymphomas.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69999239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/2329-6917.19.7.257
Elżbieta Patkowska, A. Szczepaniak, M. Barańska, M. Kaźmierczak, M. Paluszewska, W. Jędrzejczak, R. Guzicka-Kazimierczak, Wanda Knopińska-Posłuszny, O. Grzybowska‐Izydorczyk, A. Pluta, J. Piszcz, I. Dereń-Wagemann, E. Lech-Maranda, J. Góra-tybor
Introduction: Central Nervous System involvement (CNSi) in patients with Acute Myeloid Leukemia (AML) rarely occurs. It is not well characterized clinically and lacks standardized treatments. Patients and methods: A retrospective analysis of 77 consecutive AML patients with primary and secondary CNSi during 2004-2016 was performed in eight Polish haematological centres. Results: 77 patients (38 with primary CNSi-AML) were included. Median age was 44 years in both groups. Elevated lactate dehydrogenase activity was found in the majority of subjects. Patients in primary CNSi-AML group more often had myelomonocytic and monoblastic AML subtypes (68.4%) compared to secondary CNSi AML (43.5%) (p=0.039). There were no differences between both groups in the number of leukocytes or the proportion of blast cells rates in peripheral blood or bone marrow at AML diagnosis. There were also no statistically significant differences between both groups in the incidence of cytogenetic or molecular abnormalities. In both groups, CNSi was most frequently found in the cerebrospinal fluid and the most common neurological symptom was headache. The following manifestations were more frequent in secondary than in primary CNSi-AML: lower extremity weakness (38.46% vs. 13.16%; p=0.023), paraesthesia (38.46% vs. 13.16%; p=0.023), motor deficits (31.58% vs. 10.53%; p=0.047), and asymmetry of reflexes (26.32% vs. 2.7%; p=0.007). Median pleocytosis was also significantly higher in secondary than in primary CNSi-AML: 27 (IQR 2-146) vs. 2 (IQR: 1-12; p=0.004). Both groups had rather short Overall Survival (OS), with a median of 16.6 months (9.9-NA) for patients with primary CNSi-AML and 15.4 months (10.1-21.1) for patients with secondary CNSi. Conclusion: Patients with CNSi AML were relatively young, having high lactate dehydrogenase activity and high rates of the myelomonocytic and monoblastic/monocytic AML subtypes. The advisability of undertaking CNS examination and prophylaxis in patients with such characteristics thus merits further reassessment.
简介:中枢神经系统受累(CNSi)在急性髓性白血病(AML)患者中很少发生。临床特征不明确，缺乏规范的治疗方法。患者和方法:回顾性分析了2004-2016年期间在波兰8个血液学中心连续发生的77例原发性和继发性CNSi AML患者。结果:纳入77例患者(38例原发性CNSi-AML)。两组患者的中位年龄均为44岁。大多数受试者乳酸脱氢酶活性升高。与继发性CNSi AML(43.5%)相比，原发性CNSi-AML组患者更常发生髓单核细胞和单细胞AML亚型(68.4%)(p=0.039)。在AML诊断时，两组在外周血或骨髓中白细胞数量或母细胞比例率方面没有差异。两组在细胞遗传学或分子异常发生率上也没有统计学上的显著差异。在两组中，CNSi最常见于脑脊液，最常见的神经系统症状为头痛。继发性CNSi-AML的以下表现比原发性CNSi-AML更常见:下肢无力(38.46%比13.16%;P =0.023)，感觉异常(38.46% vs. 13.16%;P =0.023)，运动障碍(31.58% vs. 10.53%;P =0.047)，反射不对称性(26.32% vs. 2.7%;p = 0.007)。继发性CNSi-AML的中位胞数也显著高于原发性CNSi-AML: 27 (IQR: 2-146) vs. 2 (IQR: 1-12;p = 0.004)。两组患者的总生存期(OS)都很短，原发性CNSi- aml患者的中位生存期为16.6个月(9.9 na)，继发性CNSi患者的中位生存期为15.4个月(10.1-21.1)。结论:CNSi AML患者相对年轻，乳酸脱氢酶活性高，骨髓单核细胞和单核细胞/单核细胞AML亚型发生率高。因此，对具有这些特征的患者进行中枢神经系统检查和预防的可取性值得进一步重新评估。
{"title":"Primary and Secondary Central Nervous System Involvement in Acute Myeloid Leukemia","authors":"Elżbieta Patkowska, A. Szczepaniak, M. Barańska, M. Kaźmierczak, M. Paluszewska, W. Jędrzejczak, R. Guzicka-Kazimierczak, Wanda Knopińska-Posłuszny, O. Grzybowska‐Izydorczyk, A. Pluta, J. Piszcz, I. Dereń-Wagemann, E. Lech-Maranda, J. Góra-tybor","doi":"10.35248/2329-6917.19.7.257","DOIUrl":"https://doi.org/10.35248/2329-6917.19.7.257","url":null,"abstract":"Introduction: Central Nervous System involvement (CNSi) in patients with Acute Myeloid Leukemia (AML) rarely occurs. It is not well characterized clinically and lacks standardized treatments. Patients and methods: A retrospective analysis of 77 consecutive AML patients with primary and secondary CNSi during 2004-2016 was performed in eight Polish haematological centres. Results: 77 patients (38 with primary CNSi-AML) were included. Median age was 44 years in both groups. Elevated lactate dehydrogenase activity was found in the majority of subjects. Patients in primary CNSi-AML group more often had myelomonocytic and monoblastic AML subtypes (68.4%) compared to secondary CNSi AML (43.5%) (p=0.039). There were no differences between both groups in the number of leukocytes or the proportion of blast cells rates in peripheral blood or bone marrow at AML diagnosis. There were also no statistically significant differences between both groups in the incidence of cytogenetic or molecular abnormalities. In both groups, CNSi was most frequently found in the cerebrospinal fluid and the most common neurological symptom was headache. The following manifestations were more frequent in secondary than in primary CNSi-AML: lower extremity weakness (38.46% vs. 13.16%; p=0.023), paraesthesia (38.46% vs. 13.16%; p=0.023), motor deficits (31.58% vs. 10.53%; p=0.047), and asymmetry of reflexes (26.32% vs. 2.7%; p=0.007). Median pleocytosis was also significantly higher in secondary than in primary CNSi-AML: 27 (IQR 2-146) vs. 2 (IQR: 1-12; p=0.004). Both groups had rather short Overall Survival (OS), with a median of 16.6 months (9.9-NA) for patients with primary CNSi-AML and 15.4 months (10.1-21.1) for patients with secondary CNSi. Conclusion: Patients with CNSi AML were relatively young, having high lactate dehydrogenase activity and high rates of the myelomonocytic and monoblastic/monocytic AML subtypes. The advisability of undertaking CNS examination and prophylaxis in patients with such characteristics thus merits further reassessment.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69999222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/2329-6917.19.7.255
Issa Hajji Ally, Ting Yang, Ji, A. Hu
Burkitt Lymphoma (BL) is an uncommon but highly aggressive B-cell Non-Hodgkin Lymphoma (NHL). It is a subtype of mature B-cell lymphoma and can be treated successfully within a short period via high-intensity chemotherapeutic regimens. Diagnosis and initial work-up must be completed rapidly to begin treatment due to high proliferation. BL is associated with the Epstein-Barr Virus (EBV) and with a chromosomal translocation that activates the c-MYC gene. However, by implementing chemotherapy regimens, complete remission and overall survival for young patients with BL remains high. In contrast, in elderly patients and those with relapsed/refractory disease, the prognosis remains a medical challenge. Rituximab, the chimeric monoclonal antibody against CD20, has improved the clinical management of B-cell malignancies. Because BL expresses a CD20 positive marker in their cell surfaces, rituximab has been shown to improve patient survival rate. However, because resistance can still occur, further treatment and evaluation is required, including inhibition of the MYC proto-oncogene through the use of bromodomain inhibitors. In this review, we highlight the treatment advances and progress in BL.
{"title":"Treatment Advances for Burkitt Lymphoma","authors":"Issa Hajji Ally, Ting Yang, Ji, A. Hu","doi":"10.35248/2329-6917.19.7.255","DOIUrl":"https://doi.org/10.35248/2329-6917.19.7.255","url":null,"abstract":"Burkitt Lymphoma (BL) is an uncommon but highly aggressive B-cell Non-Hodgkin Lymphoma (NHL). It is a subtype of mature B-cell lymphoma and can be treated successfully within a short period via high-intensity chemotherapeutic regimens. Diagnosis and initial work-up must be completed rapidly to begin treatment due to high proliferation. BL is associated with the Epstein-Barr Virus (EBV) and with a chromosomal translocation that activates the c-MYC gene. However, by implementing chemotherapy regimens, complete remission and overall survival for young patients with BL remains high. In contrast, in elderly patients and those with relapsed/refractory disease, the prognosis remains a medical challenge. Rituximab, the chimeric monoclonal antibody against CD20, has improved the clinical management of B-cell malignancies. Because BL expresses a CD20 positive marker in their cell surfaces, rituximab has been shown to improve patient survival rate. However, because resistance can still occur, further treatment and evaluation is required, including inhibition of the MYC proto-oncogene through the use of bromodomain inhibitors. In this review, we highlight the treatment advances and progress in BL.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69998636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/2329-6917.19.7.256
K. Eman, Eel, Y. Madney, A. Amin, A. Kamel
Background Minimal Residual Disease (MRD) is the most important prognostic parameter in pediatric precursor B cell- Acute Lymphoblastic Leukemia (B-ALL). However, the feasibility of flow cytometry in the detection of Minimal Residual Disease (MRD) in T cell- Acute Lymphoblastic Leukemia (T-ALL) is not well defined. Objectives We aimed to investigate the prognostic impact of Flow Cytometry-MRD in T-ALL measured at different time points post-induction. Patients and methods In the current study, the impact of MRD was investigated in 58 newly diagnosed pediatric ALL at day 15, 28 and 42 post induction treatment in relation to other clinical and hematological parameters as well as disease-free survival. Results At day 15, day 28 and day 42 patients with MRD level ≥ 0.1% had inferior Disease-Free Survival (DFS) compared to patients with lower MRD levels which was significant for day 15, day 28 and 42 (p=0.007, p=0.0148 and p=0.0004 respectively). No association was detected between MRD status and different clinical and laboratory parameters. Conclusion Post-induction MRD detection is sensitively reflecting the disease progression in pediatric (T-ALL). This is most evident at day 42 followed by day 15.
{"title":"Role of Minimal Residual Disease in the Clinical Course of T cell Acute Lymphoblastic Leukemia in Pediatric Patients","authors":"K. Eman, Eel, Y. Madney, A. Amin, A. Kamel","doi":"10.35248/2329-6917.19.7.256","DOIUrl":"https://doi.org/10.35248/2329-6917.19.7.256","url":null,"abstract":"Background Minimal Residual Disease (MRD) is the most important prognostic parameter in pediatric precursor B cell- Acute Lymphoblastic Leukemia (B-ALL). However, the feasibility of flow cytometry in the detection of Minimal Residual Disease (MRD) in T cell- Acute Lymphoblastic Leukemia (T-ALL) is not well defined. Objectives We aimed to investigate the prognostic impact of Flow Cytometry-MRD in T-ALL measured at different time points post-induction. Patients and methods In the current study, the impact of MRD was investigated in 58 newly diagnosed pediatric ALL at day 15, 28 and 42 post induction treatment in relation to other clinical and hematological parameters as well as disease-free survival. Results At day 15, day 28 and day 42 patients with MRD level ≥ 0.1% had inferior Disease-Free Survival (DFS) compared to patients with lower MRD levels which was significant for day 15, day 28 and 42 (p=0.007, p=0.0148 and p=0.0004 respectively). No association was detected between MRD status and different clinical and laboratory parameters. Conclusion Post-induction MRD detection is sensitively reflecting the disease progression in pediatric (T-ALL). This is most evident at day 42 followed by day 15.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69999051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-04-16DOI: 10.4172/2329-6917.1000248
A. G. Martins
Guidelines for the treatment of testicular recurrences need to be changed: a patient with unilateral testicular recurrence of ALL has been unnecessarily castrated by irradiation. The patient has been free of disease for 12 years, having had chemotherapy, several bone marrow transplants and left Orchyepididimectomy. Nevertheless, due to irradiation of the right testicle, he has been left permanently under hormonal replacement and with unavoidable infertility. This outcome could have been avoided if treatment guidelines had been changed and a different approach was taken. This confirms some more recent studies, although with the drawback of the number of affected patients being small.
{"title":"Testicular Relapse in Acute Lymphoblastic Leukemia (ALL): Guidelines Must be Changed","authors":"A. G. Martins","doi":"10.4172/2329-6917.1000248","DOIUrl":"https://doi.org/10.4172/2329-6917.1000248","url":null,"abstract":"Guidelines for the treatment of testicular recurrences need to be changed: a patient with unilateral testicular recurrence of ALL has been unnecessarily castrated by irradiation. The patient has been free of disease for 12 years, having had chemotherapy, several bone marrow transplants and left Orchyepididimectomy. Nevertheless, due to irradiation of the right testicle, he has been left permanently under hormonal replacement and with unavoidable infertility. This outcome could have been avoided if treatment guidelines had been changed and a different approach was taken. This confirms some more recent studies, although with the drawback of the number of affected patients being small.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"6 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2018-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44160107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-03-15DOI: 10.4172/2329-6917.1000247
T. Mahjoub
Sana Mahjoub1, Rabeb Ghali1, Vera Chaeib1, Bechir Achour2, Fatma Megdich1, Malek Souayed1, Faouzi Janhanni1, Abdelaziz Soukri3, Wassim Y Almawi4 and Touhami Mahjoub1* 1Laboratory of Human Genome and Multifactorial Diseases (LR12ES07), Faculty of Pharmacy of Monastir, Haifa Regaieg University of Monastir 2Hematology Clinical departments CHU Farhat Hached Sousse 3Professor Laboratoire de Physiopathologie, Génétique moléculaire et Biotechnologie PGMBessor Casablanca Maroc 4Faculty of Sciences, El-Manar University, Tunis, Tunisia *Corresponding author : Touhami Mahjoub, Laboratory of Human Genome and Multifactorial Diseases (LR12ES07), Faculty of Pharmacy of Monastir, University of Monastir, Tunisia, Tel: +0021698246153; E-mail: touhamimahjoub@gmail.com
Sana Mahjoub1、Rabeb Ghali1、Vera Chaeib1、Bechir Achour2、Fatma Megddich1、Malek Souayed1、Faouzi Janhanni1、Abdelaziz Soukri3、Wassim Y Almawi4和Touhami Mahjoub1*1人类基因组和多因子疾病实验室（LR12ES07），莫纳斯提尔药学院，Haifa Regaieg Monastir大学2医学临床系CHU Farhat Hached Sousse 3物理病理实验室教授，Génétique moléculaire et Biotechnologie PGMBessor Casablanca Maroc 4科学学院，El Manar大学，突尼斯突尼斯突尼斯*通讯作者：Touhami Mahjoub，人类基因组和多因素疾病实验室（LR12ES07），突尼斯莫纳斯特大学莫纳斯特药学院，电话：+0021698246153；电子邮件：touhamimahjoub@gmail.com
{"title":"CDKN2A and CDKN2B Gene Variants in Acute Lymphoblastic Leukemia in Tunisian Population","authors":"T. Mahjoub","doi":"10.4172/2329-6917.1000247","DOIUrl":"https://doi.org/10.4172/2329-6917.1000247","url":null,"abstract":"Sana Mahjoub1, Rabeb Ghali1, Vera Chaeib1, Bechir Achour2, Fatma Megdich1, Malek Souayed1, Faouzi Janhanni1, Abdelaziz Soukri3, Wassim Y Almawi4 and Touhami Mahjoub1* 1Laboratory of Human Genome and Multifactorial Diseases (LR12ES07), Faculty of Pharmacy of Monastir, Haifa Regaieg University of Monastir 2Hematology Clinical departments CHU Farhat Hached Sousse 3Professor Laboratoire de Physiopathologie, Génétique moléculaire et Biotechnologie PGMBessor Casablanca Maroc 4Faculty of Sciences, El-Manar University, Tunis, Tunisia *Corresponding author : Touhami Mahjoub, Laboratory of Human Genome and Multifactorial Diseases (LR12ES07), Faculty of Pharmacy of Monastir, University of Monastir, Tunisia, Tel: +0021698246153; E-mail: touhamimahjoub@gmail.com","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"6 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2018-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000247","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42969222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-27DOI: 10.4172/2329-6917.1000246
Alvarado Ibarra Martha, Mena Zepeda Veronica, Ortiz Zepeda Maricela, A. José, Espitia Ríos Maria, J. A. Rosa, L. Antonio
The purpose of this study was to report the therapeutic results obtained from prospective protocols at the Hematology Service of our hospital, over the course of this century, before new drugs were used. All patients underwent chemotherapy (only one recent group also received rituximab). All LCL patients taken care of at the Hematology Service of the National Medical Center (CMN) “20 de Noviembre”, ISSSTE. Patients included in this study were diagnosed with LCL and met the following criteria: persistent lymphocytosis above 5 × 109/L, for more than three months; typical lymphocytic morphology, with less than 10% of immature forms; immunophenotype of B strain with CD5, CD19, CD 79a, CD 20, CD22, CD23, CD24, CD25 + low-intensity SmIg; 30%+ lymph cells in the bone marrow. From 2001 to late 2016, 2’857patients were taken care of de novo. Out of these patients, 61 were diagnosed with LCL (2.1%). Twenty-four patients suffered from chronic diseases when LCL was diagnosed; Diabetes Mellitus type 2 in 14 patients; uremia in 4 patients, heart disease in 3 patients; the remaining ones were systemic high blood pressure (2) and rheumatoid arthritis (1). Until 2004, the first-line therapeutic treatment was CL only. CF was applied for the next four years (until 2008). Lastly, CFR is used until 2016. The lack of remission is only noticed when no treatment was administered or CL or CF treatment was administered. The best responses were achieved with CFR (p=0.0001). CL toxicity was found once only (neutropenia). There were two incidents with CF: neutropenia and pancytopenia. CFR was related to two cases of pancytopenia (p= 0.52). In the multivaried analysis, lymphocytic leukocytosis was a negative predictor for SLP and SG and lymph cell count for the bone marrow. Therefore, lymphocytic leukocytosis is the most frequent variable related to the forecast. It seems reasonable that being a benchmark of the neoplastic level it may be used as a reliable indicator. However, this finding has not been consistent, although other authors have reported it. Compared against the new forecasting data and new drugs, the variables herein are applicable only if used as per the treatments used herein. With new drugs, new forecast data are to be used.
{"title":"Long-term Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Standard Therapy","authors":"Alvarado Ibarra Martha, Mena Zepeda Veronica, Ortiz Zepeda Maricela, A. José, Espitia Ríos Maria, J. A. Rosa, L. Antonio","doi":"10.4172/2329-6917.1000246","DOIUrl":"https://doi.org/10.4172/2329-6917.1000246","url":null,"abstract":"The purpose of this study was to report the therapeutic results obtained from prospective protocols at the Hematology Service of our hospital, over the course of this century, before new drugs were used. All patients underwent chemotherapy (only one recent group also received rituximab). \u0000All LCL patients taken care of at the Hematology Service of the National Medical Center (CMN) “20 de Noviembre”, ISSSTE. Patients included in this study were diagnosed with LCL and met the following criteria: persistent lymphocytosis above 5 × 109/L, for more than three months; typical lymphocytic morphology, with less than 10% of immature forms; immunophenotype of B strain with CD5, CD19, CD 79a, CD 20, CD22, CD23, CD24, CD25 + low-intensity SmIg; 30%+ lymph cells in the bone marrow. \u0000From 2001 to late 2016, 2’857patients were taken care of de novo. Out of these patients, 61 were diagnosed with LCL (2.1%). Twenty-four patients suffered from chronic diseases when LCL was diagnosed; Diabetes Mellitus type 2 in 14 patients; uremia in 4 patients, heart disease in 3 patients; the remaining ones were systemic high blood pressure (2) and rheumatoid arthritis (1). \u0000Until 2004, the first-line therapeutic treatment was CL only. CF was applied for the next four years (until 2008). Lastly, CFR is used until 2016. The lack of remission is only noticed when no treatment was administered or CL or CF treatment was administered. The best responses were achieved with CFR (p=0.0001). \u0000CL toxicity was found once only (neutropenia). There were two incidents with CF: neutropenia and pancytopenia. CFR was related to two cases of pancytopenia (p= 0.52). \u0000In the multivaried analysis, lymphocytic leukocytosis was a negative predictor for SLP and SG and lymph cell count for the bone marrow. Therefore, lymphocytic leukocytosis is the most frequent variable related to the forecast. It seems reasonable that being a benchmark of the neoplastic level it may be used as a reliable indicator. However, this finding has not been consistent, although other authors have reported it. Compared against the new forecasting data and new drugs, the variables herein are applicable only if used as per the treatments used herein. With new drugs, new forecast data are to be used.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"6 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2018-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000246","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48392985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：